RxDoctor Payments Data

Julie Davisson, APRN

Psychiatric/Mental Health · The Villages, FLNPI 1366874109

Payments from drug & device makers

$2,501in general payments, 2019–2025

Across 81 payments — averaging $30.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$760
  • AbbVie$722
  • Axsome Therapeutics, Inc.$339
  • Neurocrine Biosciences, Inc.$291
  • AstraZeneca$86
  • Otsuka America Pharmaceutical, Inc.$83
  • plus $220 from 7 others

What the payments were for

  • Food & beverage$2,501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,501 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$34,222
Medicare patients
82
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl25$36,370
Lurasidone Hcl29$4,528
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$2,298
Lamotrigine114$1,381
Quetiapine Fumarate74$1,335
Duloxetine Hcl46$1,058
Buspirone Hcl65$1,057
Aripiprazole37$1,028
Clonazepam90$796
Venlafaxine Hcl ErVenlafaxine Hcl33$778
Sertraline Hcl133$698
Trazodone Hcl88$652
Fluoxetine Hcl85$648
Bupropion XlBupropion Hcl32$569
Hydroxyzine Hcl39$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$722$36,37025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →